Park Avenue Securities’s Bio-Techne TECH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-5,283
Closed -$276K 1826
2026
Q1
$276K Sell
5,283
-3
-0.1% -$180 ﹤0.01% 1352
2025
Q4
$311K Buy
5,286
+478
+10% +$29K ﹤0.01% 1304
2025
Q3
$267K Sell
4,808
-436
-8% -$23.4K ﹤0.01% 1460
2025
Q2
$270K Buy
+5,244
New +$264K ﹤0.01% 1315
2025
Q1
Sell
-10,493
Closed -$756K 1499
2024
Q4
$756K Sell
10,493
-1,642
-14% -$121K 0.01% 890
2024
Q3
$970K Sell
12,135
-2,066
-15% -$155K 0.01% 701
2024
Q2
$1.02M Buy
14,201
+649
+5% +$47.8K 0.01% 661
2024
Q1
$954K Buy
13,552
+62
+0.5% +$4.44K 0.01% 692
2023
Q4
$1.04M Buy
13,490
+1,234
+10% +$81.3K 0.01% 605
2023
Q3
$834K Buy
12,256
+1,421
+13% +$112K 0.01% 631
2023
Q2
$884K Buy
10,835
+799
+8% +$64.2K 0.01% 519
2023
Q1
$745K Sell
10,036
-2,616
-21% -$202K 0.01% 541
2022
Q4
$1.05M Sell
12,652
-8
-0.1% -$635 0.02% 502
2022
Q3
$899K Buy
12,660
+776
+7% +$67.1K 0.02% 490
2022
Q2
$1.03M Sell
11,884
-436
-4% -$40.9K 0.02% 450
2022
Q1
$1.33M Sell
12,320
-828
-6% -$85.4K 0.02% 379
2021
Q4
$1.7M Sell
13,148
-72
-0.5% -$8.83K 0.03% 307
2021
Q3
$1.6M Buy
13,220
+832
+7% +$101K 0.03% 284
2021
Q2
$1.39M Buy
12,388
+380
+3% +$40K 0.03% 298
2021
Q1
$1.15M Buy
12,008
+1,576
+15% +$144K 0.03% 304
2020
Q4
$828K Buy
10,432
+908
+10% +$65.8K 0.02% 336
2020
Q3
$590K Buy
9,524
+1,324
+16% +$86.1K 0.02% 396
2020
Q2
$541K Buy
8,200
+1,792
+28% +$107K 0.02% 382
2020
Q1
$304K Buy
6,408
+1,232
+24% +$61.6K 0.03% 240
2019
Q4
$284K Buy
+5,176
New +$272K 0.01% 479

Other funds holding TECH

Park Avenue Securities's TECH Position: Q2 2026 in Review

Park Avenue Securities sold out of Bio-Techne (TECH) in Q2 2026, closing a stake of 5,283 shares — an estimated $276K sold.

Park Avenue Securities first reported a position in TECH in Q4 2019 and held it in 25 quarters. The position peaked at $1.7M in Q4 2021. 174 funds tracked by Wall St. Rank hold TECH as of Q2 2026.

  • Park Avenue Securities reported no remaining Bio-Techne position as of Q2 2026 after selling out during the quarter.
  • Park Avenue Securities sold 5,283 Bio-Techne shares in Q2 2026, an estimated $276K.
  • Park Avenue Securities first reported a position in Bio-Techne in Q4 2019 and held it in 25 quarters.
  • Park Avenue Securities's Bio-Techne position peaked at $1.7M in Q4 2021.
  • 174 funds tracked by Wall St. Rank held Bio-Techne as of Q2 2026.

Based on Park Avenue Securities's 13F filing for Q2 2026, filed 20 Jul 2026.